-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Nurix Therapeutics, Lowers Price Target to $25

Benzinga·04/09/2025 18:01:25
Listen to the news
Wells Fargo analyst Derek Archila maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and lowers the price target from $32 to $25.